Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD5 | P21918 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 8/20 | 0.35 |
| ▸ | SCN1A | P35498 | 7/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1770010 | 0.83 | DRD2 (0.50) | DRD2DRD4DRD3MAPK1 | |
| SCHEMBL3824484 | 0.76 | DRD3 (0.44) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL5131769 | 0.76 | DRD3 (0.44) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL3824489 | 0.76 | DRD3 (0.44) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL1769731 | 0.75 | DRD2 (0.46) | DRD2DRD4 | |
| SCHEMBL3818073 | 0.74 | DRD2 (0.45) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL11592645 | 0.71 | DRD2 (0.53) | DRD2 | |
| SCHEMBL11594479 | 0.71 | DRD2 (0.66) | DRD2DRD4DRD3OPRM1OPRK1 | |
| SCHEMBL3824487 | 0.67 | RORC (0.40) | DRD2DRD4DRD3 | |
| SCHEMBL22165423 | 0.67 | MEN1 (0.39) | DRD2DRD1DRD4DRD5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112104-A1 | TRICYCLIC COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | LES LABORATOIRES SERVIER (FR) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112104-A1 | TRICYCLIC COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | BAX, CASP3, BCL2 | DRD2 2186/4885DRD1 1752/4885DRD4 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.